Psychiatr. praxi. 2021;22(3):143-148 | DOI: 10.36290/psy.2021.031

Clinical experience with newer antipsychotics

MUDr. Jakub Vaněk
Klinika psychiatrie Fakultní nemocnice Olomouc

Psychotic disorders are among the serious psychiatric disorders with far-reaching negative consequences for the patient and society. Each new drug that expands the armamentarium for modern psychiatry greatly helps in treatment. Modern antipsychotics are effective and safe drugs. However, in the therapy of psychotic disorders, there are still has specific areas that we cannot influence in a sufficiently targeted manner. In the last three years, three new antipsychotics have been introduced in the Czech Republic. The first of these is cariprazine released in 2019, second is lurasidone released in spring 2020 and, most recently, brexpiprazole in autumn 2020. In the following text, individual antipsychotics are discussed in terms of their pharmacological profile, side effects and indications. Furthermore, the article also presents our experience with the new drugs in everyday praxis, and a case report.

Keywords: antipsychotics, cariprazine, lurasidone, brexpiprazole, schizophrenia.

Published: October 14, 2021  Show citation

ACS AIP APA ASA Harvard Chicago Chicago Notes IEEE ISO690 MLA NLM Turabian Vancouver
Vaněk J. Clinical experience with newer antipsychotics. Psychiatr. praxi. 2021;22(3):143-148. doi: 10.36290/psy.2021.031.
Share...
Download citation
  • BibTeX (.bib)
  • Bookends (.ris)
  • EasyBib (.ris)
  • EndNote (.enw)
  • EndNote 8 (.xml)
  • ISI WoS (.isi)
  • Medlars (.medlars)
  • Mendeley (.ris)
  • MODS (.xml)
  • Papers (.ris)
  • RefWorks (.txt)
  • RefManager (.ris)
  • RIS (.ris)
  • MS Word (.xml)
  • Zotero (.ris)
    • Open full article

    References

    1. Murray CJL, Lopez AD. The Global Burden of Disease, Harvard University Press, Cambridge, MA 1996. p. 21.
    2. McGrath J, et al. Schizophrenia: a concise overview of incidence, prevalence, and mortality. Epidemiologic reviews, 2008; 30(1): 67-76. Go to original source... Go to PubMed...
    3. Cloutier M, et al. The economic burden of schizophrenia in the United States in 2013. The Journal of clinical psychiatry, 2016; 77(6): 764-771. Go to original source... Go to PubMed...
    4. Fischer, B A, Buchanan R W. Schizophrenia in adults: Epidemiology and pathogenesis. U: UpToDate, Post TW ur. UpToDate [cit. 4. 2. 2021]. Waltham, MA: UpToDate, 2021.
    5. Fischer BA, Buchanan RW. Schizophrenia in adults: clinical manifestations, course, assessment, and diagnosis. UpToDate [cit. 4. 2. 2021]. Wolters Kluwer, 2021.
    6. Huhn M, et al. Comparative efficacy and tolerability of 32 oral antipsychotics for the acute treatment of adults with multi‑episode schizophrenia: a systematic review and network meta‑analysis. The Lancet, 2019; 394.10202: 939-951. Go to original source... Go to PubMed...
    7. Higashi K, et al. Medication adherence in schizophrenia: factors influencing adherence and consequences of nonadherence, a systematic literature review. Therapeutic advances in psychopharmacology, 2013; 3(4): 200-218. Go to original source... Go to PubMed...
    8. Ema.europa.eu. 2019. Souhrn údajů o přípravku. [online] Available at: [cit. 4. 2. 2021].
    9. Kane JM, et al. Efficacy and safety of cariprazine in acute exacerbation of schizophrenia: results from an international, phase III clinical trial. Journal of clinical psychopharmacology, 2015; 35(4): 367-373. Go to original source... Go to PubMed...
    10. Vraylar (cariprazine) [prescribing information]. Madison, NJ: Allergan USA Inc; May 2019 [cit. 4. 2. 2021].
    11. Gyertyán I, et al. Cariprazine (RGH-188), a potent D3/D2 dopamine receptor partial agonist, binds to dopamine D3 receptors in vivo and shows antipsychotic‑like and procognitive effects in rodents. Neurochemistry international, 2011; 59(6): 925-935. Go to original source... Go to PubMed...
    12. Durgam S, et al. An 8-week randomized, double‑blind, placebo‑controlled evaluation of the safety and efficacy of cariprazine in patients with bipolar I depression. American Journal of Psychiatry, 2016; 173(3): 271-281. Go to original source... Go to PubMed...
    13. Németh G, et al. Cariprazine versus risperidone monotherapy for treatment of predominant negative symptoms in patients with schizophrenia: a randomised, double‑blind, controlled trial. The Lancet, 2017; 389.10074: 1103-1113. Go to original source... Go to PubMed...
    14. Masopust J, et al. Kariprazin: profil nového antipsychotika. Psychiatrie 2019; 23(1): 38-46.
    15. Ema.europa.eu. 2019. Summary of product characteristics. [online] Available at: [cit. 4. 2. 2021].
    16. Latuda (lurasidone) [prescribing information]. Marlborough, MA: Sunovion Pharmaceuticals Inc; December 2019 [cit. 4. 2. 2021].
    17. Ustohal L, Hořínková J. Lurasidon v léčbě pacienta se schizofrenií a metabolickým syndromem. Česká a Slovenská Psychiatrie, 2020; 116. 5.
    18. Tandon R, et al. A double‑blind, placebo‑controlled, randomized withdrawal study of lurasidone for the maintenance of efficacy in patients with schizophrenia. Journal of Psychopharmacology, 2016; 30(1): 69-77. Go to original source... Go to PubMed...
    19. Goldman R, et al. Efficacy and safety of lurasidone in adolescents with schizophrenia: a 6-week, randomized placebo‑controlled study. Journal of child and adolescent psychopharmacology, 2017; 27(6): 516-525. Go to original source... Go to PubMed...
    20. Suppes T, et al. Lurasidone for the treatment of major depressive disorder with mixed features: a randomized, double‑blind, placebo‑controlled study. American Journal of Psychiatry, 2016; 173(4): 400-407. Go to original source... Go to PubMed...
    21. Mohr P, Masopust J. Lurasidon: Profil antipsychotika druhé generace. Psychiatrie 2019; 23(4): 197-204.
    22. Ema.europa.eu. 2020. Summary of product information. [online] Available at: [cit. 4. 2. 2021].
    23. Rexulti (brexpiprazole) [prescribing information]. Rockville, MD: Otsuka America Pharmaceutical Inc; March 2020 [cit. 4. 2. 2021].
    24. Correll CU, et al. Efficacy and safety of brexpiprazole for the treatment of acute schizophrenia: a 6-week randomized, double‑blind, placebo‑controlled trial. American Journal of Psychiatry, 2015; 172(9): 870-880. Go to original source... Go to PubMed...
    25. Frampton JE. Brexpiprazole: a review in schizophrenia. Drugs, 2019; 79(2): 189-200. Go to original source... Go to PubMed...
    26. Wen XJ, et al. Meta‑analysis on the efficacy and tolerability of the augmentation of antidepressants with atypical antipsychotics in patients with major depressive disorder. Brazilian Journal of Medical and Biological Research, 2014; 47(7): 605-616. Go to original source... Go to PubMed...
    27. Grossberg GT, et al. Efficacy and safety of brexpiprazole for the treatment of agitation in Alzheimer's dementia: two 12-week, randomized, double‑blind, placebo‑controlled trials. The American Journal of Geriatric Psychiatry, 2020; 28(4): 383-400. Go to original source... Go to PubMed...
    28. Kopeček M, Mohr P, Masopust J. Brexpiprazol: profil nového antipsychotika ze skupiny parciálních agonistů dopaminu. Psychiatrie 2020; 24(2): 93-102.

    Return to the content


    Psychiatry for Practice

    Madam, Sir,
    please be aware that the website on which you intend to enter, not the general public because it contains technical information about medicines, including advertisements relating to medicinal products. This information and communication professionals are solely under §2 of the Act n.40/1995 Coll. Is active persons authorized to prescribe or supply (hereinafter expert).
    Take note that if you are not an expert, you run the risk of danger to their health or the health of other persons, if you the obtained information improperly understood or interpreted, and especially advertising which may be part of this site, or whether you used it for self-diagnosis or medical treatment, whether in relation to each other in person or in relation to others.

    I declare:

    1. that I have met the above instruction
    2. I'm an expert within the meaning of the Act n.40/1995 Coll. the regulation of advertising, as amended, and I am aware of the risks that would be a person other than the expert input to these sites exhibited

    No
    Yes

    If your statement is not true, please be aware
    that brings the risk of danger to their health or the health of others.